Anthos Therapeutics company information, Employees & Contact Information

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion Blackstone

Abelacimab Cuts AF Bleeding Risk Across Ages with Christian Ruff, MD, MPH HCPLive

Novartis Strikes Deal to Acquire Anthos Therapeutics Pharmaceutical Executive

Anthos Therapeutics Shares New Analysis from the Landmark GlobeNewswire

Abelacimab Benefits Spectrum of Bleeding Risk with Siddharth Patel, MD, MPH HCPLive

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Novartis

Anthos Therapeutics' novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine PR Newswire

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion - WSJ The Wall Street Journal

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa Wiley Online Library

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC Diagnostic and Interventional Cardiology

Blackstone explores sale of Anthos Therapeutics -sources Reuters

Novartis buys back Anthos Therapeutics for up to $3.1B Medical Marketing and Media

Novartis to buy Anthos Therapeutics in $3.1 bn deal Yahoo Finance

Anthos Therapeutics Appoints Will Kane as President and GlobeNewswire

Anthos Therapeutics Appoints Drew Young as Chief Commercial Officer and Head of Patient Experience PR Newswire

Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions Diagnostic and Interventional Cardiology

Anthos Therapeutics Announces Appointment of Bill Meury as CEO GlobeNewswire

Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer PR Newswire

Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention PR Newswire

Anthos Therapeutics Appoints David McIntyre as Chief Financial Officer PR Newswire

Christian T. Ruff, MD, MPH: Abelacimab Limits Bleeding Events in AZALEA–TIMI 71 Trial HCPLive

Novartis to Acquire Anthos Therapeutics Contract Pharma

Abelacimab Demonstrates "Overwhelming" Efficacy vs Rivaroxaban in Phase 2b Trial HCPLive

Patient-relevant bleeds ‘can be life-altering’ for many anticoagulant users Healio

Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding HCPLive

Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront BioSpace

Novartis to Acquire Anthos Therapeutics CHEManager

Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition BioSpace

AZALEA-TIMI 71 Trial Shows Abelacimab Significantly Reduces Bleeding Events vs. Xarelto in AFib Patients Applied Clinical Trials

Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation Business Wire

Anthos Therapeutics Unveils Additional Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating that the Factor XI Inhibitor Abelacimab was Associated with Remarkably Low Levels of Periprocedural Bleeding in Patients with Atrial Fibrillation Business Wire

Novartis to Acquire Anthos Therapeutics with $925 Million Upfront Payment BioPharm International

Novartis to pay $3.1B for Cambridge biotech led by former Karuna CEO The Business Journals

Driving Innovation in Life Sciences: Building Anthos Therapeutics Blackstone

Anthos Therapeutics is Developing a Hemostasis-Sparing Anticoagulant to Reduce the Hazard of Bleeding BioSpace

Novartis to acquire Blackstone-backed Anthos Therapeutics for up to $3.1 billion CNBC TV18

Novartis and Blackstone Launch Anthos Therapeutics With $250 Million BioSpace